The bottom line is few companies can match its combination of established leadership in rare diseases and realistic pathways ...

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), with its substantial $114.5 billion market capitalization, continues to dominate the cystic fibrosis (CF) treatment market while advancing a ...

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX), a leading biotechnology company specializing in cystic fibrosis (CF) treatments, has been making significant strides in expanding its therapeutic portfolio ...

Cantor Fitzgerald analyst Olivia Brayer maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $480.00. The company’s shares closed ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%.

Vertex Pharmaceuticals Inc. (NASDAQ ... itself as a dominant player in the CF treatment market, with a strong product lineup that continues to drive revenue growth. The company's focus on ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report), with a price target of $402.00. The company’s ...

Vertex Pharmaceuticals stock declined almost 13 ... Consistent Rise in VRTX’s CF Product Sales Vertex’s cystic franchise (“CF”) sales continue to grow, driven by higher sales of Trikafta ...

Notably, Vertex Pharmaceuticals (NASDAQ ... Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. Those who already own the stock may retain it ...

Vertex Pharmaceuticals Incorporated ... Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.